298 related articles for article (PubMed ID: 19492147)
21. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
22. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.
Blombäck M; He S; Bark N; Wallen HN; Elg M
Br J Haematol; 2011 Mar; 152(6):758-65. PubMed ID: 21250974
[TBL] [Abstract][Full Text] [Related]
23. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
Adiguzel C; Iqbal O; Hoppensteadt D; Jeske W; Cunanan J; Litinas E; He Zhu ; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009 Oct; 15(5):501-11. PubMed ID: 19703818
[TBL] [Abstract][Full Text] [Related]
24. The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies.
Membre A; Wahl D; Latger-Cannard V; Max JP; Lacolley P; Lecompte T; Regnault V
Haematologica; 2008 Apr; 93(4):566-73. PubMed ID: 18322249
[TBL] [Abstract][Full Text] [Related]
25. A critical role for thrombin in platelet aggregation under high shear stress.
Sakurai Y; Shima M; Giddings J; Takeyama M; Kasuda S; Nogami K; Nishiya K; Yoshioka A
Thromb Res; 2004; 113(5):311-8. PubMed ID: 15183043
[TBL] [Abstract][Full Text] [Related]
26. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
27. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
[TBL] [Abstract][Full Text] [Related]
28. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Sørensen B; Ingerslev J
Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
[TBL] [Abstract][Full Text] [Related]
29. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
[TBL] [Abstract][Full Text] [Related]
32. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulant activity of the novel thrombin inhibitor 1-butyl-3-(6,7-dimethoxy-2-naphthylsulfonyl) amino-3-(3-guanidinopropyl)-2-pyrrolidinone hydrochloride.
Okayama T; Araki S; Miyamae T; Morita Y; Morikawa T; Hagiwara M
Arzneimittelforschung; 1997 Sep; 47(9):1023-6. PubMed ID: 9342415
[TBL] [Abstract][Full Text] [Related]
34. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
35. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of prothrombin activation by bothrojaracin, a C-type lectin from Bothrops jararaca venom.
Monteiro RQ; Zingali RB
Arch Biochem Biophys; 2000 Oct; 382(1):123-8. PubMed ID: 11051105
[TBL] [Abstract][Full Text] [Related]
37. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.
Tsiang M; Paborsky LR; Li WX; Jain AK; Mao CT; Dunn KE; Lee DW; Matsumura SY; Matteucci MD; Coutré SE; Leung LL; Gibbs CS
Biochemistry; 1996 Dec; 35(51):16449-57. PubMed ID: 8987977
[TBL] [Abstract][Full Text] [Related]
38. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
Kaiser B; Jeske W; Walenga JM; Fareed J
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
[TBL] [Abstract][Full Text] [Related]
40. In vitro effects of human neutrophil cathepsin G on thrombin generation: Both acceleration and decreased potential.
Perrin J; Lecompte T; Tournier A; Morlon L; Marchand-Arvier M; Vigneron C
Thromb Haemost; 2010 Sep; 104(3):514-22. PubMed ID: 20589323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
